WALTHAM, Mass.--(BUSINESS WIRE)--Small molecule drug discovery acceleration experts and DNA-encoded library (DEL) technology pioneers X-Chem, Inc. welcomes Paul Davie as Chief Business Officer. He will lead global business development, focusing on the creation of new market opportunities for the company’s innovative technology platform and shaping new business ventures, collaborations and strategic partnerships to maximize the value of X-Chem’s digital drug discovery technology platform..

马萨诸塞州沃尔瑟姆（商业新闻短讯）--小分子药物发现加速专家和DNA编码文库（DEL）技术先驱X-Chem，Inc.欢迎保罗·戴维斯担任首席商务官。他将领导全球业务发展，专注于为公司的创新技术平台创造新市场机会，并塑造新的商业风险、合作和战略伙伴关系，以最大限度地发挥X-Chem数字药物发现技术平台的价值。。

Davie, who joins X-Chem from Schrödinger, has an established record of building and growing successful business operations through innovative strategic partnerships that provide unique, data driven solutions and significant year-on-year growth.

Davie从Schrödinger加入X-Chem，他通过创新的战略合作伙伴关系建立和发展成功的业务运营，提供独特的数据驱动解决方案和显着的同比增长。

“To deliver on our strategy of using our market-leading digital and experimental drug discovery platforms, the right strategic partnerships are essential,” said Karen Lackey, Chief Executive Officer of X-Chem. “I’m excited that Paul — with his deep expertise and strong global network — joins us as our platforms continue evolving with new capabilities that enable our partners to achieve discovery program success.”.

X-Chem首席执行官凯伦·拉基（KarenLackey）表示：“为了实现我们使用市场领先的数字和实验药物发现平台的战略，正确的战略合作伙伴关系至关重要。”。“我很高兴Paul凭借其深厚的专业知识和强大的全球网络加入我们，因为我们的平台不断发展，拥有新的功能，使我们的合作伙伴能够取得探索计划的成功。”。

“I am thrilled to join the X-Chem team and help deliver on its ambitious plans,” Davie added. “The combination of the world’s leading DEL hit-finding platform, hugely skilled medicinal chemistry teams and powerful AI-driven informatics capabilities singularly positions X-Chem as an outstanding partner for cost-effective drug discovery acceleration.”.

。“世界领先的DEL hit发现平台，技能娴熟的药物化学团队和强大的人工智能驱动的信息学能力的结合，使X-Chem成为成本效益高的药物发现加速的杰出合作伙伴。”。

X-Chem’s mission is to leverage its leading drug discovery platform — which combines DEL screening with AI-supported computational analysis and world class medicinal chemistry — to accelerate molecules through the discovery process. Its application of digital modalities enables scientists to make faster, smarter decisions, reducing time to clinic based on comprehensive arrays of data..

。它对数字模式的应用使科学家能够做出更快，更智能的决定，减少基于全面数据阵列的临床时间。。

About X-Chem

关于X-Chem

X-Chem is the leader in small molecule discovery, providing pharmaceutical and biotech companies a complete, seamless solution for screening, hit validation and lead optimization. As a pioneer of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform and proprietary artificial intelligence platform, ArtemisAI, to discover novel small molecule leads for challenging, high-value therapeutic targets.

X-Chem是小分子发现领域的领导者，为制药和生物技术公司提供完整、无缝的筛选、命中验证和铅优化解决方案。作为DNA编码化学文库（DEL）技术的先驱，该公司利用其市场领先的DEL平台和专有的人工智能平台ArtemisAI，发现具有挑战性的高价值治疗靶点的新型小分子线索。

The company’s expertise in medicinal chemistry, custom synthesis and scale-up process chemistry supports all aspects of small-molecule drug discovery through candidate identification..

该公司在药物化学，定制合成和放大过程化学方面的专业知识通过候选鉴定支持小分子药物发现的各个方面。。